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Context: P450 oxidoreductase (POR) is a crucial electron donor to all microsomal P450 cytochrome
(CYP) enzymes including 17-hydroxylase (CYP17A1), 21-hydroxylase (CYP21A2) and P450 aro-
matase. Mutant POR causes congenital adrenal hyperplasia with combined glucocorticoid and sex
steroid deficiency. P450 oxidoreductase deficiency (ORD) commonly presents neonatally, with
disordered sex development in both sexes, skeletal malformations, and glucocorticoid deficiency.
Objective: The aim of the study was to describe the clinical and biochemical characteristics of ORD
during puberty.
Design: Clinical, biochemical, and genetic assessment of seven ORD patients (five females, two
males) presenting during puberty was conducted.
Results: Predominant findings in females were incomplete pubertal development (four of five) and
large ovarian cysts (five of five) prone to spontaneous rupture, in some only resolving after combined
treatment with estrogen/progestin, GnRH superagonists, and glucocorticoids. Pubertal development
inthetwoboyswasmoremildlyaffected,withsomespontaneousprogression.Urinarysteroidprofiling
revealed combined CYP17A1 and CYP21A2 deficiencies indicative of ORD in all patients; all but one
failed tomount an appropriate cortisol response to ACTH stimulation indicative of adrenal insufficiency.
Diagnosis ofORDwas confirmedbydirect sequencing,demonstratingdisease-causingPORmutations.
Conclusion: Delayed and disordered puberty can be the first sign leading to a diagnosis of ORD.
Appropriate testosterone production during puberty in affected boys but manifest primary hy-
pogonadism ingirlswithORDmay indicate that testicular steroidogenesis is less dependentonPOR
than adrenal and ovarian steroidogenesis. Ovarian cysts in pubertal girls may be driven not only
by high gonadotropins but possibly also by impaired CYP51A1-mediated production of meiosis-
activating sterols due to mutant POR. (J Clin Endocrinol Metab 96: 0000–0000, 2011)
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Abbreviations: CYP, Cytochrome P450; CYP51A1, lanosterol 14-demethylase; DHEA, de-
hydroepiandrosterone;DHEAS,DHEAsulfate;DSD,disordered sexdevelopment; E2, estradiol;
FF-MAS, follicular fluid MAS; GC/MS, gas chromatography/mass spectrometry; 17HP, 17-
hydroxypregnanolone; 5-HT, pregnenetriol; MAS, meiosis-activating sterol; 17OHP, 17-hy-
droxyprogesterone; ORD, POR deficiency; PD, pregnanediol; POR, P450 oxidoreductase; PT,
pregnanetriol; P’TONE, pregnanetriolone; THA, tetrahydro-11-dehydrocorticosterone; THB,
tetrahydrocorticosterone; THE, tetrahydrocortisone; THF, tetrahydrocortisol.
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P450 oxidoreductase (POR) deficiency (ORD) is a vari-ant of congenital adrenal hyperplasia caused by mu-
tations in the POR gene (1–3). POR encodes the electron
donor enzyme POR that transfers electrons from reduced
nicotinamide adenine dinucleotide phosphate to all mi-
crosomal cytochrome P450 (CYP) enzymes;mutations re-
sult in impaired steroid and sterol synthesis and metabo-
lism. Clinically, ORD manifests with disordered sex
development (DSD), adrenal insufficiency, and skeletal
malformations (1–5).
The skeletal malformations in ORD patients resemble
the malformation phenotype of Antley-Bixler syndrome
(OMIM 207410) (6). The malformation phenotype in
ORD is thought to reflect impaired activities of POR-de-
pendent enzymes involved in cholesterol synthesis and
retinoic acid metabolism (7–10), including lanosterol
14-demethylase (CYP51A1), squalene epoxidase, and
CYP26 subfamily members. In ORD patients, combined
deficiencies of the steroidogenic enzymes CYP17A1 and
CYP21A2 represent the most striking biochemical find-
ings. Steroid 21-hydroxylase (CYP21A2) catalyzes crucial
steps of adrenal gluco- andmineralocorticoid production.
CYP17A1 is expressed in adrenals and gonads and cata-
lyzes 17-hydroxylase and17,20-lyase activities, required
for glucocorticoid and sex steroid synthesis, respectively.
Notably, ORD patients of both sexes may present at birth
withDSD.Male undervirilization, i.e. 46,XYDSD, can be
readily explained by inhibition of CYP17A1, which re-
sults in decreased androgen production. Masculinization
of affected females, i.e. 46,XX DSD, is a more puzzling
finding because circulating androgen levels are usually
low. This apparent contradiction could possibly be ex-
plained by the presence of an alternative pathway toward
active androgen synthesis, which is active only during hu-
man fetal development (2). Elements of this proposed al-
ternative pathway have been previously found in the fetal
gonad of the tammar wallaby (11). P450 aromatase
(CYP19A1), the microsomal CYP enzyme responsible for
the conversion of androgens to estrogens, also depends on
electron transfer fromPOR. In the fetus, loss of aromatase
activity due to inactivating CYP19A1 mutations is asso-
ciated with maternal virilization due to placental aro-
matase deficiency, virilization of the female fetus (46,XX
DSD), and disordered pubertal development in females
(12). The broad variability in phenotypicmanifestation of
ORD may well be explained by differential inhibition of
thevariousPOR-dependentCYPenzymesbydistinctPOR
mutants (13, 14).
Neonatal presentation inORDhas beenwell described
(2, 4, 5, 15, 16). However, there is a paucity of detailed
data on the pubertal phenotype that is likely to be affected
by impaired sex steroid synthesis. Herewe present seven pa-
tients (five females, twomales) withORDand describe their
clinical and biochemical characteristics during puberty.
Patients and Methods
Patients
The cohort consisted of five female and two male patients
from six different countries. In all patients, appropriate written
consent and assent, respectively, had been obtained in accor-
dance with local Institutional Review Board guidelines. Patient
characteristics including genetic and biochemical findings are
summarized inTable 1 for the affected girls and inTable 2 for the
two male patients.
Case 1
The neonatal presentation of this case, virilized genitalia
(46,XXDSD) and low circulating androgens, has been described
previously (2). At the age of 14 yr, the patient presented with
acute abdominal pain. Investigations revealed rupture of a large
(4.5 cm) left ovarian cyst requiring surgical intervention, with
removal of a largely degenerative polycystic ovary. Physical ex-
amination also revealed mild dysmorphic features (depressed
nasal bridge, arachnodactyly, camptodactyly, restricted elbow
extension bilaterally, syndactyly of toes 2/3). Tanner stageswere
PH4, B4, and M0. However, serum estradiol (E2) was prepu-
bertal and gonadotropins were high (Table 1). 17-Hydroxypro-
gesterone (17OHP) and progesterone were elevated, cortisol
showed a subnormal response to ACTH1-24 (Table 1), and hy-
drocortisone cover during stress was recommended. After 6
months of treatment with synthetic progestin, E2 levels slightly
increased, but gonadotropins were still high (E2, 106 pmol/liter;
LH, 15.3 U/liter; FSH, 8 U/liter). Treatment was changed to an
E2/progestin combination. Follow-up 1 yr later showed low E2
levels and elevated gonadotropins (E2, 63 pmol/liter; LH, 40
U/liter; FSH, 16 U/liter), possibly reflecting compliance problems.
At the age of 15.8 yr, spontaneous rupture of a right ovarian cyst
occurred that required emergency surgical intervention resulting in
the removal of the residual right ovary. The patient now receives
continuous estrogen/progestin replacement therapy.
Case 2
Thepatient (46,XX)was born after 42wkgestation as the third
child of nonconsanguineous parents of Polish origin. Her genitalia
wasvirilizedatbirth(clitoromegalyandurogenitalsinus).Attheage
of 11.5 yr, bilateral ovarian masses were diagnosed by ultrasound
and computed tomography and subsequently surgically removed.
Histopathology confirmed ovarian follicular cysts. Endocrine as-
sessmentrevealedundetectableE2andelevatedLHandFSH(Table
1). After 10 months, ovarian cysts on both sides recurred, and the
patient was referred for further endocrine investigations. Tanner
stages were B1, PH2, and M0. Several dysmorphic features were
noted, including midface hypoplasia, brachycephaly, dysplastic
ears, arachno- and camptodactyly, and bilaterally restricted elbow
extension.Hormonal assessment showedelevated17OHP,proges-
terone,andACTHconcentrations;however, cortisolwashigh-nor-
mal at baseline and after iv cosyntropin (Table 1). Medical treat-
mentof theovariancystswithacombinationofE2(1mg/d),GnRH
superagonist (Diphereline, 3.75 mg/month), and dexamethasone
(0.25 mg/d; reduction to 0.125 mg/48 h after 2 months) was initi-
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ated. On this regimen, the ovarian cysts partially regressed in size
after 12 months of treatment. At 13.5 yr, the patient’s pubertal
staging was B4, PH3; she was then started on a combination of
triamcinolone2mg/d, 17-E2, and synthetic progestin, resulting in
regular withdrawal bleeds. The ovarian cysts further decreased in
size, and until the present age of 18 yr there have been no
recurrences.
Case 3
The patient was born with ambiguous genitalia after an un-
eventful pregnancy to consanguineous parents of Italian origin.
The baby was raised as a boy until the age of 5 when her gender
assignment was reconsidered after the birth of a sister with ob-
vious 46,XX DSD. A diagnostic laparotomy showed the pres-
ence of normal internal female genital organs. Multiple genital
corrective surgeries including vaginoplasty and partial clitoral
reduction were performed between 5 and 12 yr of age. Normal
psychomotor development, bone age, and growth velocity (50th
to 75th percentile) were documented. Her younger sister later
died at age 8 yr after developing signs and symptoms of shock
shortly after undergoing an appendectomy.
Pubertal development was induced at the age of 17 yr by
treatment with equine estrogens and progesterone. At the age of
23 yr, she was assessed as having normal female appearance but
with only moderate breast development (Table 1). Several mild
dysmorphic features were noted (narrow hard palate, low-set
ears, clinodactyly, camptodactyly, and brachydactyly of the
fourth toe bilaterally). Genetic analysis confirmed a 46,XX
karyotype. Hormonal evaluation showed elevated serum pro-
gesterone and 17OHP levels, whereas serum androgens were
low; serum cortisol was low at baseline and did not increase
appropriately after iv cosyntropin (Table 1). After 3 months of
estrogenwithdrawal, thepatient’s gonadotropinswere increased
(LH, 53 U/liter; FSH, 29 U/liter). Concurrently, large ovarian
cysts up to 7 cm in diameter developed,which regressed partially
after reintroduction of estrogen/progestin treatment, but only
resolved after the addition of glucocorticoid treatment (dexa-
methasone, 0.375 mg/d).
Case 4
The patient was the first child born to nonconsanguineous
parents of Dutch origin. There was no genital ambiguity, but she
underwent early postnatal assessment for dysmorphic features,
including frontal bossing, midface hypoplasia, pear-shaped
nose, low-set ears with flat helices, impaired supination of the
forearms, arachnodactyly, and synostosis of several distal and
interphalangeal joints. However, no precise diagnosis was es-
tablished, and she was subsequently lost to follow-up.
TABLE 1. Summary of clinical, genetic, and hormonal findings in five female pubertal ORD patients
Case 1 Case 2 Case 3 Case 4 Case 5
Ethnicity White Caucasian White Caucasian White Caucasian White Caucasian White Caucasian
Karyotype 46,XX 46,XX 46,XX 46,XX 46,XX
POR mutations (p.) A287P/R457H A287P/A287P A287P/A287P T142A/Y376 LfsX74 A287P/R223X
46,XX DSD Yes Yes Yes No Yes
Skeletal malformations Mild Mild Mild Overt at birth Overt at birth
Age at investigation (yr) 16 12 23 19 16
Tanner stages PH4, B4, M0 PH2, B1, M0 PH3, B3, M0 PH3, B5, M1 PH3, B3, M0
Height (cm) 168 (0.9 SDS) 148 (1.4 SDS) 166 (0.4 SDS) 182.5 (2.0 SDS) 158.7 (0.7 SDS)
Target height (cm) 168 (0.9 SDS) 61 (0.9 SDS) 1545 (1.5 SDS) 175 (0.8 SDS) 169.5 (0.5 SDS)
Weight (kg) 51.3 (0.7 SDS) 32.0 (2.2 SDS) 61.4 (0.3 SDS) 88.0 (3.1 SDS) 40.2 (2.4 SDS)
BMI (kg/m2) 18.2 (0.9 SDS) 14.61 (2.1 SDS) 22.3 (0.5 SDS) 26.3 (1.5 SDS) 16.1 (2.3 SDS)
ACTH (pmol/liter) 3.1 (2.2–11) 34.8 (2.2–11) 22 (2.2–11) 19 (2.2–11) 5.3 (2.2–11)
Cortisol (nmol/liter)
Baseline 289 (150–780) 607 (150–780) 149 (150–780) 375 (150–780) 190 (120–780)
60 min after 250 g
ACTH1-24 iv
436 (550) 717 (550) 158 (550) 425 (550) 314 (550)
Adrenal insufficiency Yes No Yes Yes Yes
Progesterone
(nmol/liter)
Baseline 8.8 (0.9–2.3) 256 (0.3–14.1) 45.8 (3) 58 (0.9–2.3) 28.8 (0.1–5.1)
60 min after 250 g
ACTH1-24 iv
53.4 307 181.5 83 191
17OHP (nmol/liter)
Baseline 25.7 (0.45–2.9) 72.7 (0.45–2.9) 67.5 (5) 25 (0.45–2.9) 15 (0.1–8.1)
60 min after 250 g
ACTH1-24 iv
53.4 86.8 82.3 36 n.m.
Androstenedione
(nmol/liter)
2.6 (1.8–12.9) 3.45 (2.8–6.6) n.m. 0.6 (3.0–9.6) 1.7 (0.1–5.5)
DHEAS (mol/liter) 5.7 (1.1–6.2) 2.41 (0.8–9.3) 2 (2.5–5.25) 1,2 (3.0–13.0) 4.2 (0.4–7.9)
Testosterone
(nmol/liter)
n.m. n.m. 0.48 (2.4) 1.1 (1.0–3.5) 0.48 (0.1–1.7)
E2 (pmol/liter) 53.5 (78–312) Undetectable n.m. 90 (70–530) 84 (66–246)
LH (U/liter) 35.0 (1.1–3.7) 19.0 (0.3–1.2) 53.0 (0.7–4.7) 6.1 (1.1–3.7) 19.2 (0.7–4.7)
FSH (U/liter) 12.6 (3.1–8.1) 17.0 (1.6–7.3) 29.0 (3.9–7.0) 10.0 (3.1–8.1) 13.1 (3.9–7.0)
n.m., Not measured; SDS, SD score.
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At the age of 19 yr, she presented with irregular menses. Pu-
bertal development was partially delayed (Table 1). Hormonal
assessment revealed lowE2withnormal gonadotropins; 17OHP
andprogesteronewere elevated;baseline cortisolwasnormalbut
did not increase sufficiently after iv cosyntropin, and adrenal
androgens were low (Table 1). A magnetic resonance imaging
scan of the pelvic region revealed cystic enlargement of the right
ovary (3  4 cm) with normal appearance of the left ovary and
normal female anatomy of the reproductive system. Combined
treatment with E2 (2 mg daily) and dydrogesterone (10 mg/d)
was initiated. At present, the patient has been on hormone re-
placement therapy for 12 months, and repeat imaging revealed
complete regression of the ovarian cyst.
Case 5
The girl was born at 36 wk gestation after an uneventful
pregnancy to nonconsanguineous parents of German origin.
Postnatally, the girl needed ventilation due to severe respiratory
distress associated with bilateral choanal stenosis. At birth there
were obvious dysmorphic features including brachycephaly,
midface hypoplasia, exophthalmus, retrognathia, depressed na-
sal bridge, low-set ears, and bilateral radiohumeral synostosis.
The external genitaliawere ambiguouswith clitoral hypertrophy
and an urogenital sinus (Prader stage III). Clitoral reduction and
vulvo- and vaginoplasty were performed at 2 yr of age. During
childhood, the girl had multiple reconstructive surgeries for cor-
rection of the craniofacial abnormalities.
At 16 yr of age, she presented to the endocrine clinic because
of primary amenorrhea. Tanner staging revealed PH3, B3, and
M0. Bone agewas delayed by 2 yr. Pelvic ultrasound revealed an
infantile uterus and bilateral polycystic ovaries with the largest
cystmeasuring 1 cm in diameter andwith increased total ovarian
volumes of 8.6 and 10 ml, respectively. Hormonal analysis
showed a lowE2with up-regulated gonadotropins; baseline cor-
tisol was low and did not increase sufficiently after iv cosyn-
tropin, and adrenal androgens were normal (Table 1). She was
started on E2 valerate for hormone replacement.
Case 6
This boy was born at 39 wk gestation as the first child of a
Chinese mother and a Costa Rican father. Both testes were un-
descended but palpable in the inguinal canal; the scrotum was
hypoplastic.Bilateral orchidopexieswereperformedat theageof
12 months. In addition, at birth, choanal stenosis, facial dys-
morphism (brachycephaly, frontal bossing, mid-face hypopla-
sia, preauricular skin tags), and multiple skeletal abnormalities,
including arachnodactyly, shoulder and knee contractures, ra-
dioulnar synostosis, bilateral coronal synostosis, and partial fu-
sions of thoracic vertebrae T3/T4, were noted. No conclusive
diagnosis was made, and the patient was lost to follow-up.
The patient was referred for endocrine assessment at the age
of 10.5 yr because of poor genital development (Table 2). His
genitalia were undermasculinized for age (phallus of 15 mm
length with little erectile tissue). Serum gonadotropins and an-
drogen levels were prepubertal (Table 2). Cortisol was normal at
baseline but insufficiently stimulated after 250 g ACTH1–24
revealing partial adrenal insufficiency (Table 2).Hydrocortisone
replacement therapy (10 mg/m2 daily) and early pubertal induc-
tion with oral testosterone (40 mg/d) were commenced, but the
family then dropped out of care and ceased medications.
At age 16 yr, the patient presented again after several years of
no medication. However, pubertal development had spontane-
ously progressed, and the phallus was 8.5 cm with adequate
erectile tissue, appropriate testicular volumes, and advanced pu-
TABLE 2. Summary of clinical, genetic, and hormonal findings in two male pubertal ORD patients
Case 6 Case 7
Ethnicity Hispanic/Asian White Caucasian
Karyotype 46,XY 46,XY
POR mutations (p.) R457H/Y576X A287P/IVS7  2dupT
46,XY DSD No, but both testicles undescended
(inguinal canal)
No, but right testicle undescended
(inguinal canal)
Skeletal malformations Overt at birth Overt at birth
Age at investigation (yr) 12 16 12 13.5
Tanner stages PH1, G1 PH5, G5 PH1, G1 PH3, G2
Testicular volume (right/left) (ml) 1/2 20/25 4/12 10/25
Height (cm) 143 (0.6 SDS) 166.1 (0.9 SDS) 138.2 (1.6 SDS) 150.9 (0.8 SDS)
Target height (cm) 178.5 (1.3 SDS) 174 (0.1 SDS)
Weight (kg) 28.7 (1.8 SDS) 39.9 (2.95 SDS) 42.5 (0.2 SDS) 56.6 (0.9 SDS)
BMI (kg/m2) 14.1 (2.3 SDS) 15.0 (3.3 SDS) 22.3 (1.3 SDS) 25.1 (1.60 SDS)
ACTH (pmol/liter) 39.6 (2.2–11) 16 (2.2–11) 12.4 (2.2–11) 99.1 (2.2–11)
Cortisol (nmol/liter)
Baseline 198 (150–780) 217 (150–780) 353 (150–780) n.m.
60 min after 250 g ACTH1-24 iv 229 (550) n.m. 411 (550) n.m.
Adrenal insufficiency Yes Yes
17OHP (nmol/liter)
Baseline 112 (6) 91.5 14 (0.45–2.9) n.m.
60 min after 250 g ACTH1-24 iv 124 n.m. 54 n.m.
Androstenedione (nmol/liter) 5.4 (1.8–12.9) 6.0 (2.7–10) 1.1 (1.8–12.9) n.m.
DHEAS (mol/liter) 0.9 (1.1–6.2) 1.9 (1.8–10) 0.8 (0.5–4.1) 1.3 (1.1–6.2)
Testosterone (nmol/liter) 0.8 (0.2–1.5) 26.6 (9–27) 0.7 (0.07–0.8) 10.7 (9–27)
LH (U/liter) 0.4 (1.7) 37 (0.2–6.1) 0.6 (1.7) 2.4 (0.4–4.6)
FSH (U/liter) 1.7 (2.5) 12.5 (0.5–6.3) 1.9 (2.5) 4.8 (2.7–4.4)
n.m., Not measured; SDS, SD score.
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bertal staging (Table 2). Hormonal investigations revealed nor-
mal androgens but up-regulated gonadotropins (Table 2).
Case 7
This boy was born after an uneventful pregnancy to noncon-
sanguineous parents of British origin. At birth, several dysmor-
phic featureswerenoted including choanal stenosis, brachyceph-
aly, and joint contractures due to radioulnar synostosis. There
was no genital ambiguity; however, his right testicle was unde-
scended but palpable in the inguinal channel. Right-sided orchi-
dopexy was undertaken at the age of 12 months, and the boy
underwent a series of osteotomies for coronal craniosynostosis.
He presented at 12 yr of age to the endocrine clinic with lack
of pubertal development and testicular volumes of 4 and 12 ml,
respectively. Adrenal androgen concentrations were low; testos-
terone was high-normal in comparison to age-specific reference
(Table 2). Baseline cortisol was normal, but response to iv co-
syntropin was insufficient (Table 2). Hydrocortisone treatment
was initiated (10 mg/m2 daily), and further pubertal develop-
ment was monitored at 6-month intervals. Puberty progressed
spontaneously, andwhen assessed at the age of 13.5 yr testicular
volumes had increased to 10 and 25 ml, respectively (Table 2).
Dehydroepiandrosterone sulfate (DHEAS), testosterone, and
baselinegonadotropinswerewithinage-specific reference ranges
(Table 2).
Urinary steroid metabolite analysis
Analysis of urinary steroid metabolite excretion was per-
formed as described previously by a quantitative gas chroma-
tography/mass spectrometry (GC/MS) selected ion-monitoring
method (2, 17). In brief, steroids were enzymatically released
from conjugation and, after extraction, chemically derivatized
before GC/MS selected ion-monitoring analysis. Steroids quan-
tified included corticosteronemetabolites [tetrahydrocorticoste-
rone (THB), 5THB, tetrahydro-11-dehydrocorticosterone
(THA), and5THA)], theprogesteronemetabolitepregnanediol
(PD), 17OHP metabolites [pregnanetriol (PT), and 17-hy-
droxypregnanolone (17HP)], the 17-hydroxypregnenolone me-
tabolite pregnenetriol (5-PT), the 21-desoxycortisol metabolite
pregnanetriolone (P’TONE), cortisol metabolites [tetrahydro-
cortisol (THF), 5THF, tetrahydrocortisone (THE)], and an-
drogen metabolites [androsterone, etiocholanolone, dehydro-
epiandrosterone (DHEA), and 16-hydroxy-DHEA].
After quantification of steroid metabolites by GC/MS, we cal-
culated substrate/product ratios to determine the approximate in
vivonet activity of specific steroidogenic enzymes: 21-hydroxylase,
100 P’TONE/(THF 5THF THE), (17HP PT)/(THF
5THF  THE); 17-hydroxylase, (THA  5THA  THB 
5THB)/(THF 5THFTHE); 17,20-lyase, (17HP PT)/(an-
drosterone  etiocholanolone); ORD-specific ratio, PD/(THF 
5THF THE). These diagnostic ratios and the overall secretion
patternswerecomparedwithurinarysteroidprofilesobtainedfrom
a normal reference cohort of boys and girls between 12 and 16 yr
of age (n 12).
Genetic analysis
The coding sequence of the POR gene including exon-intron
boundaries was amplified in 13 PCR fragments as previously
described (2). Direct sequencing was carried out employing an
automated ABI3730 Sequencer (Applied Biosystems Inc., Foster
City, CA). Sequences were analyzed using the DNAStar Laser-
gene software package (DNASTAR Inc., Madison, WI). Se-
quence variants were designated according to Human Genome
Variation Society recommendations (www.hgvs.org/rec.html)
using the reference sequences GenBank NC_000007 (g.DNA),
GenBankNM_000941.2 (c.DNA), andGenBankNP_000932.3
(protein). For DNA numbering, the nucleotide designated 1
was the A of the ATG start codon.
Results
Clinical and serum biochemical characteristics
All seven patients presented with absent or incomplete
pubertal development leading to the diagnosis of ORD.
Three female patients had presented neonatally with
46,XXDSD, and five of the seven patients had overt skel-
etal malformations noted immediately after birth. How-
ever, in all cases this had not prompted the establishment
of a conclusive diagnosis before puberty.
Generally, female patients presented with significant
pubertal impairment and ovarian cysts. In case 1, spon-
taneous cyst rupture required two surgical emergency in-
terventions, resulting in loss of both ovaries despite on-
going estrogen/progestin therapy. Ovarian cysts in cases 2
and 3 only resolved after the addition of glucocorticoids
and GnRH agonists to ongoing estrogen/progestin ther-
apy. Four of the five female patients presented with pri-
mary amenorrhea and biochemical evidence of primary
hypogonadism (Table 1). By contrast, both boys showed
spontaneous, albeit slightly delayed, pubertal progression,
with testicularvolumesappropriate forage,andbiochemical
signs of compensated hypogonadism,with normal testoster-
one but up-regulated gonadotropins (Table 2).
In all patients, adrenal androgenswere either normal or
low (Table 1). All cases had elevated 17OHP and proges-
terone concentrations, accompanied by increased ACTH
levels in five patients. Baseline cortisol secretion was nor-
mal in five patients and borderline low in two. In all but
one patient, cortisol secretion was not sufficiently stimu-
lated by iv cosyntropin, indicative of partial adrenal in-
sufficiency (Table 1).
Auxological investigations in all seven cases showed a
normal height at investigation within the familial target
height range (Table 1).
In vivo assessment of steroidogenesis by urinary
steroid profiling
Steroid profiling by GC/MS revealed a typical pattern
forORD in all patients studied (Fig. 1). Twenty-four-hour
excretion analysis revealed a characteristically increased
excretion of metabolites of 17-hydroxypregnenolone (5-
PT), progesterone (PD), and 17OHP (17HP, PT,
P’TONE) and a mild increase in mineralocorticoid pre-
cursormetabolites (e.g.THB, tetrahydrodeoxycorticoste-
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FIG. 1. In vivo steroidogenic enzyme activities in pubertal ORD patients as determined by total 24-h urinary steroid metabolite excretion (A) and
diagnostic steroid substrate/product ratios (B) measured by GC/MS and shown in comparison to an age-matched reference cohort (n  12). Box
plots represent the interquartile ranges (25th to 75th percentiles), and whiskers represent the 5th and 95th percentiles, respectively, of the
reference cohort; each pubertal ORD case is represented by specific symbols as indicated in the legend.
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rone) (Fig. 1A), which reflects the concurrent impairment
of 17-hydroxylase and 21-hydroxylase activities. In
keepingwith impaired 17,20-lyase activity, androgen and
androgen precursor metabolite excretion was decreased
or low normal (Fig. 1A). Cortisol metabolites were low or
in the lowernormal reference range, indicativeof impaired
21-hydroxylase activity (Fig. 1A). Substrate/product ra-
tios clearly demonstrated attenuation of 17-hydroxy-
lase, 17,20-lyase, and21-hydroxylase activities in all cases
examined (Fig. 1B).
Genetic confirmation of diagnosis
Sequencing analysis of thePOR gene revealed compound
heterozygous missense mutations p.A287P/p.R457H in
case 1. Cases 2 and 3 were homozygous for p.A287P,
and case 4 showed compound heterozygous mutations
comprising a missense mutation (p.T142A) and a novel
frameshift mutation resulting in a premature stop codon
(p.Y376LfsX74). Case 5 was compound heterozygous,
with a p.A287P mutation on one allele, and a novel
p.R223X nonsense mutation on the other allele.
Case 6 was compound heterozygous for p.R457H and
p.Y567X, whereas case 7 was compound heterozygous
for p.A287P and a novel duplication disrupting the splice
donor site of intron 7, IVS7 2dupT. The duplication does
not yield an alternative splice site according to splice site
prediction tool http://www.cbs.dtu.dk/services/NetGene2/,
thus resulting in translation of intron 7 until a premature
stop codon 64 aa downstream of the last exon 7 codon
(p.P277PfsX65).
Discussion
Here, we describe the clinical phenotype as well as bio-
chemical and genetic findings in seven adolescents with
ORDall presentingwith disturbed pubertal development,
manifesting with insufficient pubertal development and
primary amenorrhea in four of the five girls and delayed,
albeit spontaneously progressive, puberty in the two boys.
All five females presented with ovarian cysts. This is a
common finding in females affected by steroidogenic dis-
orders andhas been reported in 21-hydroxylase deficiency
(18, 19), 17-hydroxylase deficiency (20–22), congenital
lipoid adrenal hyperplasia due to mutant steroidogenic
acute regulatory protein (23–25), P450 aromatase defi-
ciency (26, 27), and also recently inORD (5, 28). Of note,
two infants with ORD have been described who even de-
veloped large ovarian cysts at 2 and 4 months of age,
respectively (15, 29). Excessive LH-mediated ovarian
stimulation as a consequence of primary hypogonadism is
an obvious underlying mechanism. Interestingly, girls
with congenital lipoid adrenal hyperplasia often sponta-
neously undergo puberty and have normal circulating E2
levels (23) but still present with large ovarian cysts. It has
been suggested that thismaybe the consequenceof chronic
anovulation rather than LH overstimulation (24), a con-
cept that is supported by a study in a patient with amen-
orrhea, ovarian cysts, and inactivating mutations of the
LH receptor gene (30). Similarly, multiple ovarian cysts
can be found in women with steroidogenic disorders re-
sulting in androgen excess such as 21-hydroxylase defi-
ciency (19, 31), which again could be a consequence of
chronic anovulationorpotentiallydirect androgeneffects.
A uniquemechanism driving ovarian cyst development
in females affected by ORD in addition to high gonado-
tropins resulting from estrogen deficiency might be the
disruptive impact of mutant POR on sterol synthesis and
metabolism (Fig. 2). CYP51A1 requires electron transfer
from POR for catalytic activity and catalyzes the conver-
sionof lanosterol tomeiosis-activating sterols (MAS). Fol-
licular fluid MAS (FF-MAS) has been shown to be crucial
for the resumption of oocyte meiosis at puberty and also
supports oocyte maturation (32–34). The detailed mech-
anism underlying the effects of FF-MAS on oocyte matu-
ration is not clear yet but may involve the protein kinase
C pathway (35) or hedgehog signaling pathways (36, 37).
FF-MAS is further converted to testicularMAS,which has
been found to be highly expressed in mammalian testis,
especially in spermatozoa, suggesting a role in male fer-
tility (37); however, its precise role in male human repro-
duction remains to be elucidated. Importantly, CYP51A1
is highly expressed inmurine and human gonads (38), and
its inhibition in vitro results in oocyte arrest (39). Inter-
estingly, it has recently been shown that gonadotropins
induceup-regulationofCYP51A1 inmice and rabbits (39,
40), suggesting that POR-dependent CYP51A1 may be a
crucial contributor tooocytematurationat puberty.Thus,
it is conceivable that female ORD patients have to take a
“double hit” driving ovarian cyst development, disrupted
MAS synthesis, and high gonadotropins due to low estro-
genproduction (Fig. 2). Thismaypossibly explainwhy the
cysts appeared to be more difficult to control in our pa-
tients than in patients with other steroidogenic disorders,
with two of our patients requiring long-acting glucocor-
ticoids inaddition to sex steroid replacement to control the
effects of excess LH secretion.
In contrast to the findings in the five female cases, pu-
bertal development in our twomale ORD cases was more
mildly affected. Case 6 presented with poor development
at the age of 10 yr, but subsequently he and the othermale
patient spontaneously progressed through puberty with
near normal testosterone production. This may indicate
that sex steroid production in the testicles during puberty
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is less dependent on fully functional POR than ovaries or
adrenals. Fukami et al. (5) previously reported that three
of six male ORD patients had a normal pubertal devel-
opment, whereas all seven pubertal-age girls in their co-
hort had impaired pubertal development; however, only
limited detail on the pubertal findings and no longitudinal
data were provided. The only other paper previously re-
porting on pubertal age ORD patients described two
young women aged 17 and 19 yr, one of them presenting
with normal breast development but primary amenor-
rhea, the other with complete lack of pubertal develop-
ment (29).
Interestingly, circulating androgens in our pubertal pa-
tients were relatively normal, although low androgen lev-
els in infants and younger children with ORD are well
documented (1, 2, 5). The relative increase in androgen
production at pubertal age despite POR-dependent inhi-
bition of sex steroid synthesis byCYP17A1 could possibly
be explained by increased expression of cytochrome b5
(CYB5), which acts as an allosteric facilitator of POR and
CYP17A1 (41) thereby facilitating CYP17A1 17,20-lyase
activity. CYB5 is expressed pre- and postnatally in human
adrenal and testicular tissues (42). However, its expres-
sion increases in the adrenal zona reticularis around the
age of adrenarche (43), and a similar increase in testicular
Leydig cells could enhance 17,20-lyase activity signifi-
cantly to rectify androgen production during adrenarche
and puberty despite partially impaired POR function. A
recently reported ORD case with severe neonatal 46,XY
DSD, who presented with normal adrenal androgens and
phallic catch-up growth during adrenarche, supports this
hypothesis (16).
A diagnosis of adrenal insufficiency was established in
all but one of our cases at presentation during puberty,
generally displaying normal baseline cortisol levels but
failure to respond appropriately to ACTH. Of note, de-
spite neonatal presentation with DSD of unknown origin,
none of the patients had previously undergone assessment
of adrenal function, which had put them at considerable
risk of adrenal crisis in case of intercurrent illness, inflam-
matory stress, or surgery. The untimely death of the
younger sister of case 3, who also presented with 46,XX
DSD and died at the age of 8 yr of unexplained shock after
a routine appendectomy, illustrates the dramatic conse-
quences that overlooking adrenal insufficiency can have.
Some of the phenotypic variability we observed in our
patients may be explained by the differential effects of
distinct POR mutations on electron-accepting CYP en-
zymes (13). Interestingly, the three patients with either
homozygous or compound heterozygous missense muta-
tions presented with rather mild skeletal malformations
and lack of pubertal progression. By contrast, the four
patients carrying a major loss of function mutation in ad-
dition to amissensemutation on the other allele presented
with severe skeletal malformations but only relatively
mildly impaired pubertal development. This finding will
require further genotype-phenotype analysis based on
larger cohorts. Data from the Japanese ORD cohort (5)
support the notion that the presence of a null mutation on
one allele is associated with a higher incidence of severe
malformations; however, pubertal data of this cohort are
not described in sufficient detail to compare them to our
findings.Themost commonPORmutation inCaucasians,
p.A287P (44), was found on seven alleles in five of our
FIG. 2. Schematic representation of the possible mechanisms leading to ovarian cysts in female patients with ORD. Impaired sex steroid synthesis
results in low E2 levels (right) causing hypergonadotropic hypogonadism with subsequent stimulation of the ovaries by the up-regulated
gonadotropins. In addition, mutant POR affects the cholesterol synthesis pathway due to impairment of CYP51A1 activity (left) leading to
decreased generation of MAS that are important for meiotic resumption and oocyte maturation. T-MAS, Testicular MAS. Each black arrow
indicates an enzymatic reaction; dotted crosses indicate impairment of pathway reactions; gray arrows indicate increased (or decreased) serum
levels.
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patients. p.R457H, the most common POR mutation in
Japan (5, 45), was found in two of our patients, whowere
of Polish and Chinese origin, respectively. p.A287P de-
creases 17-hydroxylase to 20–40%ofwild-type activity
but retains 70%of21-hydroxylasewild-type activity (13);
p.R457H equally disrupts CYP17A1 and CYP21A2 ac-
tivities (13). p.T142A has been reported to only mildly
impair CYP17A1 activity (4) andwas found in our case 4,
the only patient with spontaneous menarche and a con-
siderable degree of spontaneous pubertal development.
In summary, pubertal development of children with
ORD is impaired and frequently manifests with primary
hypogonadism in girls, requiringmedical induction of pu-
berty and monitoring for ovarian cyst development. Af-
fected boys may have the capacity for spontaneous pu-
bertal development justifying a primarily observatory
approach. Importantly, adequate hydrocortisone replace-
ment and stress dose cover to prevent life-threatening ad-
renal crisis is crucial in these patients. The late diagnosis of
adrenal insufficiency in our patients and the death of a
sibling likely to have suffered from ORD emphasizes the
need for concurrent assessment of adrenal and gonadal
functionnot only inORDbut also in allDSDpatientswith
an unclear diagnosis. This will facilitate early diagnosis of
partial adrenal insufficiency, thus hopefully preventing
adrenal crisis-related deaths in ORD, and timely estab-
lishment of a conclusive diagnosis in affected patients.
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